Navigation Links
QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer
Date:8/5/2011

GERMANTOWN, Maryland and HILDEN, Germany, August 5, 2011 /PRNewswire/ --

?

  • Food and Drug Administration will review therascreen® KRAS RGQ PCR Kit for use with Erbitux® (cetuximab), a metastatic colorectal cancer therapy
  • PMA follows a recent submission for use with another EGFR inhibitor drug, also in patients with metastatic colorectal cancer
  • QIAGEN achieves milestones in Personalized Healthcare with innovative companion diagnostics; FDA decisions expected in 2012

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced it has completed its second U.S. submission of the therascreen® KRAS RGQ PCR Kit for use as a companion diagnostic paired with Erbitux® (cetuximab), a leading drug for treatment of patients with metastatic colorectal cancer (mCRC). Erbitux is marketed in the United States by Bristol-Myers Squibb Company and Eli Lilly and Company. Merck KGaA has the right to market Erbitux outside the US and Canada.

QIAGEN submitted a Premarket Approval (PMA) application to the FDA for use of its innovative assay in determining which patients can be expected to benefit from Erbitux in treatment of mCRC. The first submission of the KRAS assay, earlier in July, paired QIAGEN's molecular test with another drug for treatment of metastatic colorectal cancer. Both therapies are monoclonal antibody EGFR inhibitors expected to target a range of cancers. Last year's sales of Erbitux were US$820 million, representing an 18 percent increase over 2009.

The therascreen KRAS assay reliably detects mutations of the KRAS gene, which are frequently found in human cancers. Because monoclonal antibody EGFR inhibitors are h
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9
2. QIAGEN Acquires ESE GmbH
3. WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development
4. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
5. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
6. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
7. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
8. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
9. Vycor Medical, Inc. Completes Final Close on Equity Capital Raise
10. Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd.
11. Vessix Vascular Completes $23 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 /CNW/ -   ... recalled after Health Canada tests confirmed it contains two ... (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... product from retail stores across Canada ... including for weight loss and increased energy. ...
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a leader ... first patient in its study for ischemic stroke ... Stroke Association, ischemic strokes account for 87 percent ... qualified patients in the study, entitled "Internal Research ... Allogeneic Mesenchymal Stem Cells and Intrathecal Administration of ...
(Date:12/24/2014)... -- Actavis plc (NYSE: ACT ) today ... response letter from the U.S. Food and Drug ... for the fixed-dose combination (FDC) of nebivolol and ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... a complete response letter, Actavis remains committed to ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... China, May 3, 2011 /PRNewswire-Asia/ -- Winner Medical ... Medical") a leading manufacturer of medical dressings, medical ... PurCotton® products in China, today reported that its ... the 13th China International Mother-Infant-Child Products Fair ("MICF") ...
... 3, 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: ... "OND") of the U.S. Food and Drug Administration (the "FDA") ... its appeal, the reviews of the New Drug Application (the ... of the March 22, 2010 Oncology Drugs Advisory Committee meeting ...
Cached Medicine Technology:Winner Medical Exhibited its PurCotton Retail Products at MICF 2011 in Beijing 2Winner Medical Exhibited its PurCotton Retail Products at MICF 2011 in Beijing 3Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDA's Office of New Drugs 2Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDA's Office of New Drugs 3Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDA's Office of New Drugs 4Cell Therapeutics to Re-submit Pixantrone NDA in Consideration for Accelerated Approval in Accordance with Guidance from FDA's Office of New Drugs 5
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... 2014 This is a professional and ... Sterilizers industry with a focus on the Chinese market. ... of the Sterilizers manufacturers and is a valuable source ... in the industry. This report provides a basic overview ... technology. In this part, the report presents the company ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... U.S. has enough capacity for typical season; experts less sure ... The current swine flu outbreak is raising critical questions about ... the logistics of getting it to the people who need ... cut into this fall,s production of seasonal influenza vaccine, experts ...
... 2nd Annual Disability Leadership & Policy Summit: ... to promote an exchange of ideas between people with disabilities ... health and human service professionals will convene on Wednesday, June ... speakers and their topics include: , , ...
... own, while most Americans agree both are equally ... has contributed to poorer overall family health and ... to healthcare. Two-thirds of Americans (66 percent) believe ... care of their health and their children,s health. ...
... Costs by Reducing UtilizationCOLUMBUS, Ohio, May 18 As ... healthcare costs, Quantum Health, Inc. announced that its Coordinated ... employee, or 14%, in 2008. Over the past ten ... to 4%-5% with no reduction in benefits or cost-shifting ...
... to improve navigation, functionality and user-friendliness. The new website still ... with better design and navigation, users can now access information, ... ... Neptune Beach, FL (PRWEB) May 18, 2009 ...
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
Cached Medicine News:Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:United Spinal Association's 2nd Annual Disability Leadership & Policy Summit: Health Issues and People with Disabilities 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents Than Children 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents Than Children 3Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 2Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 3Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 4Health News:International Student Insurance Announces Website Redesign 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: